Advances in the Pathogenesis and Mechanisms of Comorbidity Between Chronic Kidney Disease and Metabolic Syndrome Based on Multi-Omics Technologies
DOI:
https://doi.org/10.62836/amr.v5i1.0003Keywords:
muti-omics, chronic kidney diseases (CKD), metabolic syndrome (MS), therapeutics, precision medicineAbstract
Chronic kidney disease (CKD) is a clinical condition that involves the progressive deterioration of renal function and represents an important medical, social, and economic burden with high morbidity and mortality rates. Metabolic syndrome (MS) is a group of conditions characterized by hypertension (HTN), hyperglycaemia or insulin resistance (IR), hyperlipidaemia, and abdominal obesity. MetS is associated with a high incidence of cardiovascular events and mortality and is an independent risk factor for CKD. MetS can cause CKD or accelerate the progression of kidney disease. Recent studies have found that MetS and kidney disease have a cause-and-effect relationship. With the innovation of new technologies such as large sample population cohort and precision medicine, a large number of multi-omics studies have revealed the intricate molecular networks and genetic maps in organisms through high-throughput sequencing and in-depth mining of bioinformatics, thus laying the foundation for the accurate diagnosis of diseases and the formulation of new therapeutic strategies. Therefore, it is becoming increasingly important to elucidate the relevant mechanisms of research based on multi-omics techniques for chronic kidney disease associated with metabolic syndrome in order to develop new strategies to prevent and slow the progression of kidney disease. To further advance the treatment of chronic kidney disease with metabolic syndrome, future work should focus on a deeper understanding of nephro-metabolic comorbidity, the development of more advanced metabolomics techniques, and the design of highly effective interventions.
References
Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic Kidney Disease. Lancet 2021; 398: 786–802.
Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA 2019; 332(13): 1294–1304.
GBD Chronic Kidney Disease Collaboration. Global, Regional, and National Burden of Chronic Kidney Disease, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395: 709–733.
Kuppe C, Ibrahim MM, Kranz J, et al. Decoding Myofibroblast Origins in Human Kidney Fibrosis. Nature 2021; 589: 281–286.
Lin L, Tan W, Pan X, et al. MetS-Related Kidney Injury: A Review and Update. Frontiers in Endocrinology 2022; 13: 904001.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the MetS: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–1645.
Saklayen MG. The Global Epidemic of the Metabolic Syndrome. Current Hypertension Reports 2018; 2: 12.
Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III Update: Adjustments and Options. The American Journal of Cardiology 2005; 96: 53E–59E.
Moy FM, Bulgiba A. The Modified NCEP ATP III Criteria Maybe Better than the IDF Criteria in Diagnosing MetS among Malays in Kuala Lumpur. BMC Public Health 2010; 10: 678.
Ford ES. Prevalence of the MetS Defined by the International Diabetes Federation among Adults in the US. Diabetes Care 2005; 28: 2745–2749.
Chinese Diabetes Society. Clinical Guidelines for Prevention and Treatment of Type 2 Diabetes Mellitus in the Elderly in China (2022 Edition). Zhonghua Nei Ke Za Zhi 2022; 61: 12–50.
Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, et al. MetS and Cardiovascular Diseases: Going beyond Traditional Risk Factors. Diabetes Metabolism Research Reviews 2022; 38: e3502.
Tirandi A, Carbone F, Montecucco F, et al. The Role of MetS in Sudden Cardiac Death Risk: Recent Evidence and Future Directions. European Journal of Clinical Investigation 2022; 52: e13693.
Zhang F, Liu L, Zhang C, et al. Association of MetS and Its Components with Risk of Stroke Recurrence and Mortality: A Meta-Analysis. Neurology 2021; 97: e695–e705.
Saito T, Mochizuki T, Uchida K, et al. Metabolic Syndrome and Risk of Progression of Chronic Kidney Disease: A Single-Center Cohort Study in Japan. Heart Vessels 2013; 28(3): 323–329.
Zhao F, Yang R, Maimaitiaili R, et al. Cardiac, Macro-, and Micro-Circulatory Abnormalities in Association with Individual MetS Component: The Northern Shanghai Study. Frontiers in Cardiovascular Medicine 2021; 8: 690521.
Nilsson PM, Laurent S, Cunha PG, et al. Characteristics of Healthy Vascular Ageing in Pooled Population-Based Cohort Studies: The Global Metabolic syndrome and Artery Research Consortium. Journal of Hypertension 2018; 36: 2340–2349.
Ciardullo S, Ballabeni C, Trevisan R, et al. Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease. American Journal of Nephrology 2021; 52: 666–672.
Jadoul M, Aoun M, Imani MM. The Major Global Burden of Chronic Kidney Disease. The Lancet Global Health 2024; 12: e342-e343.
Liu YM, Xie J, Chen MM, et al. Kidney Function Indicators Predict Adverse Outcomes of COVID-19. Med 2021; 2: 38–48.e2.
Foreman KJ, Marquez N, Dolgert A, et al. Forecasting Life Expectancy, Years of Life Lost, and All-Cause and Cause-Specific Mortality for 250 Causes of Death: Reference and Alternative Scenarios for 2016-40 for 195 Countries and Territories. Lancet 2018; 392: 2052–2090.
Wu N, Qin Y, Chen S, et al. Association between MetS and Incident CKD among Chinese: A Nation-Wide Cohort Study and Updated Meta Analysis. Diabetes Metabolism Research Reviews 2021; 37: e3437.
Stenvinkel P, Shiels PG. Metabolic Syndrome in Combination with Chronic Kidney Disease—It’s a Gut Feeling. Journal of Internal Medicine 2021; 290: 1108–1111.
ASN. The Hidden Epidemic: Worldwide, over 850 Million People Suffer from Kidney Diseases. Available online: https://www.asn-online.org/news/2018/0626-Joint_Hidden_Epidem.pdf (accessed on 10 January 2025).
Boronat M, Bosch E, Lorenzo D, et al. Prevalence and Determinants of the MetS among Subjects with Advanced Nondiabetes-Related CKD in Gran Canaria, Spain. Renal Failure 2016; 38: 198–203.
Hung C-C, Zhen Y-Y, Niu S-W, et al. Predictive Value of HbA1c and MetS for Renal Outcome in Non-Diabetic CKD Stage 1–4 Patients. Biomedicines 2022; 10: 1858.
Kittiskulnam P, Thokanit NS, Katavetin P, et al. The Magnitude of Obesity and MetS among Diabetic CKD Population: A Nationwide Study. PLoS ONE 2018; 13: e0196332.
Alswat KA, Althobaiti A, Alsaadi K, et al. Prevalence of MetS among the End-Stage Renal Disease Patients on Hemodialysis. Journal of Clinical Medicine Research 2017; 9: 687–694.
Wang L, Xu X, Zhang M, et al. Prevalence of Chronic Kidney Disease in China: Results from the Sixth China Chronic Disease and Risk Factor Surveillance. JAMA Internal Medicine 2023; 183: 298–310.
Carney EF. The Impact of Chronic Kidney Disease on Global Health. Nature Reviews Nephrology 2020; 16: 251.
Tsai M-H, Hsu C-Y, Lin M-Y, et al. Incidence, Prevalence, and Duration of CKD in Taiwan: Results from a Community-Based Screening Program of 106,094 Individuals. Nephron 2018; 140: 175–184.
Centers for Disease Control and Prevention (CDC). Prevalence of Chronic Kidney Disease and Associated Risk Factors—United States 1999–2004. Morbidity & Mortality Weekly Report 2007; 56(8) 161–165.
Thomas G, Sehgal AR, Kashyap SR, et al. Metabolic Syndrome and Kidney Disease: A Systematic Review and Meta-Analysis. Clinical Journal of the American Society of Nephrology 2011; 6(10): 2364–2373.
Chen J, Kong X, Jia X, et al. Association between Metabolic Syndrome and Chronic Kidney Disease in a Chinese Urban Population. Clinica Chimica Acta 2017; 470: 103–108.
Du XH, Chen YH, Zhang LH; et al. Correlation between Metabolic Syndrome and Proteinuria in Chronic Kidney Disease. Chinese Journal of Nephrology, Dialysis & Transplantation 2018; 27(1): 12–17.
Pammer LM, Lamina C, Schultheiss UT, et al. Association of the Metabolic Syndrome with Mortality and Major Adverse Cardiac Events: A Large Chronic Kidney Disease Cohort. Journal of Internal Medicine 2021; 290: 1219–1232.
Hana’a RA, Arnona Z, Rachel, D. The MetS and Its Components Are Differentially Associated with Chronic Diseases in a High-Risk Population of 350,000 Adults: A Cross-Sectional Study. Diabetes Metabolism Research Reviews 2019; 35: e3121.
Ferkingstad E, Sulem P, Atlason BA, et al. Large-Scale Integration of the Plasma Proteome with Genetics and Disease. Nature Genetics 2021; 53: 1712–1721.
Schlosser P, Scherer N, Grundner-Culemann F, et al. Genetic Studies of Paired Metabolomes Reveal Enzymatic and Transport Processes at the Interface of Plasma and Urine. Nature genetics 2023; 55: 995–1008.
Kirita Y, Wu H, Uchimura K, et al. Cell Profiling of Mouse Acute Kidney Injury Reveals Conserved Cellular Responses to Injury. Proceedings of the National Academy of Sciences USA 2020; 117: 15874–15883.
Muto Y, Wilson PC, Ledru N, et al. Single Cell Transcriptional and Chromatin Accessibility Profiling Redefine Cellular Heterogeneity in the Adult Human Kidney. Nature Communications 2021; 12: 2190.
Baysoy A, Bai Z, Satija R, et al. The Technological Landscape and Applications of Single-Cell Multi-Omics. Nature Reviews Molecular Cell Biology 2023; 24(10): 695–713. https://doi.org/10.1038/s41580-023-00615-w.
Joy T, Hegele RA. Geneties of Metabolic Syndrome: Is There a Role for Phenomies? Current Atherosclerosis Reports 2008; 10(3): 201–208.
Henneman P, Aulchenko Y, Frants R, et al. Genetic Architecture of Plasma Adiponectin Overlaps with the Genetics of Metabolic Syndrome-Related Traits. Diabetes Care 2010; 33(4): 908–913.
Teran-Garcia M, Bouchard C. Genetics of the Metabolic Syndrome. Applied Physiology, Nutrition, and Metabolism 2007; 32(10): 89–114.
Monda KL, North KE, Hunt, SC, et al. The Genetics of Obesity and the Metabolic Syndrome. Endocrine, Metabolic & Immune Disorders-Drug Targets 2010; 10(2): 86–108.
Watanabe RM, Valle T, Hauser ER, et al. Familiality of Quantitative Metabolic Traits in Finnish Families with Non-Insulin-Dependent Diabetes Mellitus. Human Heredity 1999; 49(3): 159–168.
Pullinger CR, Aouizerat BE, Movsesyan I, et al. An Apolipoprotein AV Gene SNP Is Associated with Marked Hypertriglyceridemia among Asian-American Patients. Journal of Lipid Research 2008; 49(8): 1846–1854.
Lu X, Wang L, Lin X, et al. Genome-Wide Association Study in Chinese Identifies Novel Loci for Blood Pressure and Hypertension. Human Molecular Genetics 2015; 24(3): 865–874.
Kettunen J, Tukiainen T, Sarin AP, et al. Genome-Wide Association Study Identifies Multiple Loci Influencing Human Serum Metabolite Levels. Nature Genetics 2012; 44(3): 269–276.
Dupuis J, Langenberg C, Prokopenko I, et al. New Genetic Ioci Implicated in Fasting Glucose Homeostasis and Theirimpact on Type 2 Diabetes Risk. Nature genetics 2010; 42(2): 105–116.
Wen W, Zheng W, Okada Y, et al. Meta-Analysis of Genome-Wide Association Studies in East Asian-Ancestry Populations Identifes Four New Loci for Body Mass Index. Human Molecular Genetics 2014; 23(20): 5492–5504.
Zhou L, He M, Mo Z, et al. A Genome Wide Association Study Identifies Common Variants Associated with Lipid Levels in the Chinese Population. PLoS ONE 2013; 8(12): e82420.
Consortlum GLG. Discovery and Refinement of Loci Associated with Lipid Levels. Nature Genetics 2013; 45(11): 1274–1283.
Caussy C, Charrière S, Marçais C, et al. An APOA53′UTR Variant Associated with Plasma Triglycerides Triggers APOAs Downregulation by Creating a Functional miR-48s-5p Binding Site. American Journal of Human Genetics 2014; 94: 129–134.
Larson HN, Weiner H, Hurley TD. Disruption of the Coenzyme Binding Site and Dimer Interface Revealed in the Crystal Structure of Mitochondrial Aldehyde Dehydrogenase “Asian” Variant. Journal of Biological Chemistry 2005; 280(34): 30550–30556.
Kraja AT, Vaidya D, Pankow, JS, et al. A Bivariate Genome-Wide Approach to Metabolic Syndrome STAMPEED Consortium. Diabetes 2011; 60(4): 1329–1333.
Carty CL, Bhattacharjee S, Haessler J, et al. Comparative Analysis of Metabolic Syndrome Components in over 15,000 African Americans Identifies Pleiotropic Variants: Results from the PAGE Study. Circulation: Cardiovascular Genetics 2014; 7: 505–513. https://doi.org/10.1161/CIRCGENETICS.113.000386.
Kristiansson K, Perola M, Tikkanen E, et al. Genome-Wide Screen for Metabolicsyndrome Susceptibility Loci Reveals Strong Lipid Gene Contribution but No Evidence for Common Geneticbasis for Clustering of Metabolic Syndrome Traits. Circulation: Cardiovascular Genetics 2012; 5(2): 242–249.
Zabaneh D, Balding DJ. A Genome-Wide Association Study of the Metabolic Syndrome in Indian Asian Men. PLoS ONE 2010; 5(8): e11961.
Jeong SW, Chung M, Park SJ, et al. Genome-Wide Association Study of Metabolic Syndrome in Koreans. Genomics & Informatics 2014; 12(4): 187–194.
Kullo IJ, Andrade MD, Boerwinkle E, et al. Pleiotropic Genetic Effects Contribute to the Correlation between HDL Cholesterol, Triglycerides, and LDL Particle Size in Hypertensive Sibships. American Journal of Hypertension 2005; 18(1): 99–103.
Sivakumaran S, Agakov F, Theodoratou E, et al. Abundant Pleiotropy in Human Complex Diseases and Traits. American Journal of Human Genetics 2011; 89(5): 607–618.
Vattikuti S, Guo, J, Chow CC. Heritability and Genetic Correlations Explained by Common SNPs for Metabolic Syndrome Traits. PLoS Genetics 2012; 8(3): e1002637.
Min JL, Nicholson G, Halgrimsdottir I, et al. Coexpression Network Analysis in Abdominal and Gluteal Adipose Tissue Reveals Regulatory Genetic Loci for Metabolic Syndrome and Related Phenotypes. PLoS Genetics 2012; 8(2): e1002505.
Jirtle RL, Skinner MK. Environmental Epigenomics and Disease Susceptibility. Nature Reviews Genetics 2007; 8(4): 253–262.
Macneil LT, Walhout AJ. Gene Regulatory Networks and the Role of Robustness and Stochasticity in the Control of Gene Expression. Genome Research 2011; 21(5): 645–657.
Lindoso RS, Sandim V, Collino F, et al. Proteomics of Cell–Cell Interactions in Health and Disease. Proteomics 2016; 16(2): 328–344.
Shulaev, V. Metabolomics Technology and Bioinformatics. Briefings in Bioinformatics 2006; 7(2): 128–139.
Cisek K, Krochmal M, Klein J, et al. The Application of Multi-Omics and Systems Biology to Identify Therapeutic Targets in Chronic Kidney Disease. Nephrology Dialysis Transplantation 2016; 31(12): 2003–2011. https://doi.org/10.1093/ndt/gfv364.
Hill C, Avila-Palencia I, Maxwell AP, et al. Harnessing the Full Potential of Multi-Omic Analyses to Advance the Study and Treatment of Chronic Kidney Disease. Frontiers in Nephrology 2022; 2: 923068. https://doi.org/10.3389/fneph.2022.923068.
Ye XQ, Jia WP. Research Advances in Omics Biomarkers for Diabetic Kidney Disease. Chinese Journal of Internal Medicine 2023; 62(2): 222–226.
Song JQ, Zhou Y, Xu LL, et al. Advances and Applications of Metabolomics in Chronic Kidney Disease. Chinese Journal of Nephrology, Dialysis & Transplantation 2023; 32(6): 558–562. https://doi:10.3969/j.issn.1006-298X.2023.06.012.
Jiménez-Uribe AP, Hernández-Cruz EY, Ramírez-Magaña KJ, et al. Involvement of Tricarboxylic Acid Cycle Metabolites in Kidney Diseases. Biomolecules 2021; 11(9): 1259. https://doi.org/10.3390/biom11091259.
Zhao YY, Vaziri ND, Lin RC. Lipidomics: New insight into kidney disease. Advances in Clinical Chemistry 2015; 68: 153–175. https://doi.org/10.1016/bs.acc.2014.11.002.
Lovrečić L, Maver A, Zadel M, et al. The Role of Epigenetics in Neurodegenerative Diseases; IntechOpen: London, UK, 2013.
Von Luxburg U. A Tutorial on Spectral Clustering. Statistics and Computing 2007; 17: 395–416.
Kumar A, Rai P, Daume H. Co-Regularized Multi-View Spectral Clustering. Advances in Neural Information Processing Systems 2011; 24.
Chikhi NF. Multi-View Clustering via Spectral Partitioning and Local Refinement. Information Processing & Management 2016, 52(4): 618–627.
Li Y, Nie F, Huang H; et al. Large-Scale Multi-View Spectral Clustering via Bipartite Graph. In Proceedings of the Proceedings of the Twenty-Ninth AAAI Conference on Artificial Intelligence, Austin, TX, USA, 25–30 January 2015.
Speicher NK, Pfeifer N. Integrating Different Data Types by Regularized Unsupervised Multiple Kernel Learning with Application to Cancer Subtype Discovery. Bioinformatics 2015; 31(12): i268-i275.
Li H, Wang Q, Ke J, et al. Optimal Obesity- and Lipid-Related Indices for Predicting MetS in CKD Patients with and without Type 2 Diabetes Mellitus in China. Nutrients 2022; 14: 1334.
de Boer IH, Alpers CE, Azeloglu EU, et al. Rationale and Design of the Kidney Precision Medicine Project. Kidney Int. 2021; 99(3): 498-510. https://doi: 10.1016/j.kint.2020.08.039.
Chasapi SA, Karagkouni E, Kalavrizioti D, et al. NMR-Based Metabolomics in Differential Diagnosis of Chronic Kidney Disease (CKD) Subtypes. Metabolites, 12(6): 490. https://doi.org/10.3390/metabo12060490.
Si S, Liu H, Xu L, et al. Identification of Novel Therapeutic Targets for Chronic Kidney Disease and Kidney Function by Integrating Multi-Omics Proteome with Transcriptome. Genome Medicine 2024; 16(1): 84. https://doi.org/10.1186/s13073-024-01356-x.
Mao ZH, Gao ZX, Liu Y, et al. Single-Cell Transcriptomics: A New Tool for Studying Diabetic Kidney Disease. Frontiers in Physiology 2023; 13: 1053850. https://doi.org/10.3389/fphys.2022.1053850.
Liang JZ, Zhang J, Sun Y; et al. Proteomic Analysis of Vascular Access in Patients with Stage 5 Chronic Kidney Disease. Journal of Xi’an Jiaotong University (Medical Sciences) 2020; 41(6): 874–880.
Echefu G, Batalik L, Lukan A, et al. The Digital Revolution in Medicine: Applications in Cardio-Oncology. Current Treatment Options in Cardiovascular Medicine 2025; 27(1): 2. https://doi.org/10.1007/s11936-024-01059-x.
Caroli A, Pruijm M, Burnier M, et al. Functional Magnetic Resonance Imaging of the Kidneys: Where Do We Stand? The Perspective of the European COST Action PARENCHIMA. Nephrology Dialysis Transplantation 2018; 33: ii1-ii3. https://doi.org/10.1093/ndt/gfy181.
Xu ZG, Sha RY, Guo QW, et al. Research Progress of Functional Magnetic Resonance Imaging in Diagnosis of Chronic Kidney Disease. China Medical Device 2023; 38(4): 176–180. https://doi.org/10.3969/j.issn.1674-1633.2023.04.031.
Afshinnia F, Rajendiran TM, Soni T, et al. Impaired Beta-Oxidation and Altered Complex Lipid Fatty Acid Partitioning with Advancing CKD. Journal of the American Society of Nephrology 2018; 29: 295–306.
Beckerman P, Qiu C, Park J, et al. Human Kidney Tubule-Specific Gene Expression Based Dissection of Chronic Kidney Disease Traits. EBioMedicine 2017; 24: 267–276.
Cuevas-Delgado P, Miguel V, Lamas S, et al. Chapter 6—Metabolomics tools for biomarker discovery: Applications in chronic kidney disease. In The Detection of Biomarkers; Ozkan SA, Bakirhan NK, Mollarasouli F, Eds.; Academic Press: Cambridge, MA, USA, 2022; pp. 153–181.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Sha Meng, Ruihan Peng, Fang Wang
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivatives 4.0 International License.
